Literature DB >> 20652539

Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole.

Felice Iasevoli1, Carmine Tomasetti, Federica Marmo, Daniele Bravi, Jørn Arnt, Andrea de Bartolomeis.   

Abstract

RATIONALE: A pivotal role for glutamate in the pathophysiology and treatment of schizophrenia has been suggested. Few reports have investigated the impact of antipsychotics on postsynaptic density (PSD) molecules involved in glutamatergic transmission and synaptic remodeling. Homer is a key PSD molecule putatively implicated in schizophrenia.
OBJECTIVES: We studied the effect, in acute and chronic paradigms, of a first and a second generation antipsychotic (haloperidol and sertindole, respectively) on the expression of Homer1a and Homer-interacting PSD molecules.
RESULTS: In the acute paradigm, Homer1a expression was induced by haloperidol but not sertindole in the striatum, consistent with the less propensity of sertindole to affect nigrostriatal neurotransmission. The profile of expression of two other inducible genes, Ania3 and Arc, was highly similar to Homer1a. In the cortex, haloperidol reduced Homer1a and induced Ania3. In the chronic paradigm, striatal expression of Homer1a and Ania3 resembled that observed in the acute paradigm. In the cortex, haloperidol induced Homer1a, while sertindole did not. Homer1b expression was increased by haloperidol in the striatum and cortex whereas sertindole selectively induced Homer1b in the cortex. The expression of mGluR5 was increased by both antipsychotics. A modulation by haloperidol was also seen for PSD-95 and αCaMKII.
CONCLUSIONS: These results suggest that haloperidol and sertindole may significantly modulate glutamatergic transcripts of the postsynaptic density. Sertindole induces constitutive genes in the cortex predominantly, which may correlate with its propensity to improve cognitive functions. Haloperidol preferentially modulates gene expression in the striatum, consistent with its action at nigrostriatal projections and its propensity to give motor side effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20652539     DOI: 10.1007/s00213-010-1954-0

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  63 in total

1.  Homer 1a gene expression modulation by antipsychotic drugs: involvement of the glutamate metabotropic system and effects of D-cycloserine.

Authors:  Daniela Polese; Antonella Amato de Serpis; Alberto Ambesi-Impiombato; Giovanni Muscettola; Andrea de Bartolomeis
Journal:  Neuropsychopharmacology       Date:  2002-12       Impact factor: 7.853

Review 2.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

3.  Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol.

Authors:  Kenji Hashimoto; Yuko Fujita; Eiji Shimizu; Masaomi Iyo
Journal:  Eur J Pharmacol       Date:  2005-09-05       Impact factor: 4.432

4.  Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.

Authors:  D L Zimbroff; J M Kane; C A Tamminga; D G Daniel; R J Mack; P J Wozniak; T B Sebree; B A Wallin; K B Kashkin
Journal:  Am J Psychiatry       Date:  1997-06       Impact factor: 18.112

5.  Clozapine and haloperidol differentially regulate dendritic spine formation and synaptogenesis in rat hippocampal neurons.

Authors:  H M Critchlow; P R Maycox; J N Skepper; O Krylova
Journal:  Mol Cell Neurosci       Date:  2006-07-17       Impact factor: 4.314

6.  Homer-dependent cell surface expression of metabotropic glutamate receptor type 5 in neurons.

Authors:  Fabrice Ango; David Robbe; Jian Cheng Tu; Bo Xiao; Paul F Worley; Jean-Philippe Pin; Joël Bockaert; Laurent Fagni
Journal:  Mol Cell Neurosci       Date:  2002-06       Impact factor: 4.314

7.  Homer splice variants modulation within cortico-subcortical regions by dopamine D2 antagonists, a partial agonist, and an indirect agonist: implication for glutamatergic postsynaptic density in antipsychotics action.

Authors:  C Tomasetti; C Dell'Aversano; F Iasevoli; A de Bartolomeis
Journal:  Neuroscience       Date:  2007-08-28       Impact factor: 3.590

8.  Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol.

Authors:  X M Gao; K Sakai; C A Tamminga
Journal:  Neuropsychopharmacology       Date:  1998-11       Impact factor: 7.853

9.  Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine.

Authors:  J Arnt
Journal:  Eur J Pharmacol       Date:  1995-09-05       Impact factor: 4.432

10.  Key role of the postsynaptic density scaffold proteins Shank and Homer in the functional architecture of Ca2+ homeostasis at dendritic spines in hippocampal neurons.

Authors:  Carlo Sala; Gautier Roussignol; Jacopo Meldolesi; Laurent Fagni
Journal:  J Neurosci       Date:  2005-05-04       Impact factor: 6.167

View more
  18 in total

Review 1.  MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective.

Authors:  Andrea de Bartolomeis; Felice Iasevoli; Carmine Tomasetti; Elisabetta F Buonaguro
Journal:  Mol Neurobiol       Date:  2014-11-14       Impact factor: 5.590

2.  The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses.

Authors:  Eunice Y Yuen; Xiangning Li; Jing Wei; Masakuni Horiguchi; Herbert Y Meltzer; Zhen Yan
Journal:  Mol Pharmacol       Date:  2011-11-09       Impact factor: 4.436

Review 3.  Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches.

Authors:  Andrea de Bartolomeis; Gianmarco Latte; Carmine Tomasetti; Felice Iasevoli
Journal:  Mol Neurobiol       Date:  2013-09-03       Impact factor: 5.590

4.  Genetic variability in scaffolding proteins and risk for schizophrenia and autism-spectrum disorders: a systematic review.

Authors:  Jordi Soler; Lourdes Fañanás; Mara Parellada; Marie-Odile Krebs; Guy A Rouleau; Mar Fatjó-Vilas
Journal:  J Psychiatry Neurosci       Date:  2018-05-28       Impact factor: 6.186

Review 5.  Scaffolding proteins of the post-synaptic density contribute to synaptic plasticity by regulating receptor localization and distribution: relevance for neuropsychiatric diseases.

Authors:  Felice Iasevoli; Carmine Tomasetti; Andrea de Bartolomeis
Journal:  Neurochem Res       Date:  2012-09-19       Impact factor: 3.996

6.  Genetic variability in scaffolding proteins and risk for schizophrenia and autism-spectrum disorders: a systematic review.

Authors:  Jordi Soler; Lourdes Fañanás; Mara Parellada; Marie-Odile Krebs; Guy A Rouleau; Mar Fatjó-Vilas
Journal:  J Psychiatry Neurosci       Date:  2018-07       Impact factor: 6.186

7.  Homer1a protein expression in schizophrenia, bipolar disorder, and major depression.

Authors:  Stefan L Leber; Ida C Llenos; Christine L Miller; Jeannette R Dulay; Johannes Haybaeck; Serge Weis
Journal:  J Neural Transm (Vienna)       Date:  2017-08-16       Impact factor: 3.575

8.  Protein expression of targets of the FMRP regulon is altered in brains of subjects with schizophrenia and mood disorders.

Authors:  Timothy D Folsom; Paul D Thuras; S Hossein Fatemi
Journal:  Schizophr Res       Date:  2015-05-05       Impact factor: 4.939

Review 9.  Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins.

Authors:  A de Bartolomeis; E F Buonaguro; F Iasevoli
Journal:  Psychopharmacology (Berl)       Date:  2012-11-21       Impact factor: 4.530

10.  The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment.

Authors:  Felice Iasevoli; Carmine Tomasetti; Elisabetta F Buonaguro; Andrea de Bartolomeis
Journal:  Curr Neuropharmacol       Date:  2014-05       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.